With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
CVS — frequently asked questions
Is CVS Health Corporation overvalued?
In our latest published analysis dated 2026-05-13, CVS screens modestly overvalued. The price recorded at analysis is USD 95.2 versus our fair value of USD 86.8; the high endpoint is presented separately as potential value of USD 112. That implies roughly 8.8% downside to fair value at that date.
Our latest published report, analyzed 2026-05-13, gives CVS a fair value of USD 86.8 and a potential value of USD 112. The conclusion is triangulated across multiple valuation models and weighted by reliability for CVS Health Corporation's archetype; it is a dated research output, not a live price.
Should I buy CVS now?
Our latest published rating for CVS, analyzed 2026-05-13, is Hold. CVS Health Corporation screens modestly overvalued at the analysis-date price of USD 95.2 versus fair value of USD 86.8; potential value is USD 112. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for CVS?
The dedicated bear-case section in our report analyzed 2026-05-13 documents CVS Health Corporation's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is CVS's rating?
Our latest published rating for CVS, analyzed 2026-05-13, is Hold, with a published moat assessment of 6.5/10 (Narrow). It reflects our fair value of USD 86.8, the potential value of USD 112, and the price recorded at analysis (USD 95.2).
Bull: Successful integration of primary care assets creates a closed-loop model, expanding margins and accelerating FCF to aggressively retire debt.
Main risk
Severe MA Rate Rebasing: Persistent medical cost inflation combines with unfavorable Medicare Advantage reimbursement updates, compressing insurance margins structurally above 88% MLR without offsetting premium increases.
CVS Health is a vertically integrated healthcare behemoth spanning health insurance (Aetna), pharmacy benefit management (Caremark), and retail pharmacy. While its scale provides robust and defensive cash flow generation, near-term headwinds from Medicare Advantage rates and retail margin compression weigh on profitability.
CVS Health is a vertically integrated healthcare behemoth spanning health insurance (Aetna), pharmacy benefit management (Caremark), and retail pharmacy. While its scale provides robust and defensive cash flow generation, near-term headwinds from Medicare Advantage rates and retail margin compression weigh on profitability.
Vertical integration creating a closed-loop
Vertical integration creating a closed-loop value-based care model.
Immense scale in Pharmacy Benefit
Immense scale in Pharmacy Benefit Management via Caremark.
Cycle upside
Healthcare utilization normalizes post-pandemic while value-based care assets (Oak Street, Signify) mature and expand consolidated margins.
House recommendation
Hold. The stock trades at a premium to our intrinsically sound $86.81 fair value midpoint. While robust >$7B FCF acts as a defensive buffer, extreme leverage and Medicare Advantage margin compression strictly cap actionable upside.
Company overview
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
A combined shock of Medicare Advantage rate cuts and accelerated retail footprint deterioration. Under this stress test, free cash flow conversion drops, forcing a pause on share repurchases and straining the heavily indebted $80B balance sheet.
If MLR < 86%, hold for anticipated multiple expansion. If MLR > 88% alongside flat retail comps, expect a downward multiple revision and terminal value decay.
In-line
Hold
Trigger: In-line results
If MLR < 86%, hold for anticipated multiple expansion. If MLR > 88% alongside flat retail comps, expect a downward multiple revision and terminal value decay.
Miss
Reassess
Trigger: Downside surprise
If MLR < 86%, hold for anticipated multiple expansion. If MLR > 88% alongside flat retail comps, expect a downward multiple revision and decay.
Strict deleveraging phase following heavy M&A. Capital expenditures remain elevated at 61% of D&A for retail transformation.
§11 Position management
Sizing
Maintain as a core mature holding but strictly cap at 3-5% portfolio weight due to regulatory overhang and leverage constraints.
Risk
Trim exposure aggressively if the price artificially clears the $112 high-end bound without corresponding structural MLR improvement.
Entry tranches
Level
Action
Why
Current / pullbacks
Wait for a tangible margin of safety below $76.71 (the 7.0% implied threshold on the Base model).
§12 Investor perspectives
Bull view
Buy
Hold. Fair value is mathematically anchored at $86.81 due to vital downside FCFF penalizations. We recommend maintaining current positions given the defensive $7.8B cash-generation engine, but avoiding new capital deployment until valuation gaps close or MA headwinds tangibly recede.
Base view
Hold
While the defensive FCF floor is undeniably strong, the current $95.15 price effectively demands long-term growth assumptions (implied 8.9% via reverse DCF) that misalign with the reality of an $80B debt load and secular retail margin fade.
§14 Final recommendation
Action
Hold
Hold. Fair value is mathematically anchored at $86.81 due to vital downside FCFF penalizations. We recommend maintaining current positions given the defensive $7.8B cash-generation engine, but avoiding new capital deployment until valuation gaps close or MA headwinds tangibly recede.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Unfavorable Medicare Advantage reimbursement rates combined with elevated medical cost inflation severely squeeze insurance profitability. Persistent margin contraction undermines the integrated healthcare model, crimping overall operating income and limiting the enterprise capacity to service fixed corporate obligations.
Current:2.6% for the period ended 2025-12-31
Alert ifFalls below 2.0% over any trailing twelve-month period
Depressed cash generation leaves the enterprise unable to deleverage its massive obligations following major acquisitions. Sustained cash shortfalls would heighten balance sheet vulnerability, potentially triggering credit rating downgrades, escalating borrowing expenses, and forcing the suspension of shareholder capital returns.
Current:$7.8B trailing as of the 2026-05-13 analysis date
Alert ifDeclines below $6.0B over any trailing twelve-month period
A breakdown in operating cash conversion indicates that reported net income is not translating into realized liquidity. Diminished conversion quality constrains organic cash flow, making dividend distributions unsustainable and restricting essential capital redeployment toward internal growth or debt reduction.
Current:6.018 as of the 2026-05-13 analysis date
Alert ifFalls below 2.5x over any four-quarter measurement window
Losing major pharmacy benefit management clients or suffering legislative margin compressions destroys capital efficiency across vertically integrated business units. Returns failing to exceed financing costs erode enterprise value and undermine the rationale for large-scale vertical healthcare consolidation.
Current:2.7% as of the 2026-05-13 analysis date
Alert ifFalls below 2.0% over any trailing twelve-month period
Vertical integration creating a closed-loop value-based care model.
Moderate
02Immense scale in Pharmacy Benefit Management via Caremark. — Immense scale in Pharmacy Benefit Management via Caremark.Moderate
03Aetna's massive installed insurance member base. — Aetna's massive installed insurance member base.Moderate
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Successful integration of primary care assets creates a closed-loop model, expanding margins and accelerating FCF to aggressively retire debt. EPS multiples revert toward a 14x benchmark.
If MLR < 86%, hold for anticipated multiple expansion. If MLR > 88% alongside flat retail comps, expect a downward multiple revision and terminal value decay.
Warning level: Falls below 2.0% over any trailing twelve-month period. Unfavorable Medicare Advantage reimbursement rates combined with elevated medical cost inflation severely squeeze insurance profitability. Persistent margin contraction undermines the integrated healthcare model, crimping overall operating income and limiting the enterprise capacity to service fixed corporate obligations.
Current$7.8B trailing as of the 2026-05-13 analysis date
Why it matters
Warning level: Declines below $6.0B over any trailing twelve-month period. Depressed cash generation leaves the enterprise unable to deleverage its massive obligations following major acquisitions. Sustained cash shortfalls would heighten balance sheet vulnerability, potentially triggering credit rating downgrades, escalating borrowing expenses, and forcing the suspension of shareholder capital returns.
Warning level: Falls below 2.5x over any four-quarter measurement window. A breakdown in operating cash conversion indicates that reported net income is not translating into realized liquidity. Diminished conversion quality constrains organic cash flow, making dividend distributions unsustainable and restricting essential capital redeployment toward internal growth or debt reduction.
Warning level: Falls below 2.0% over any trailing twelve-month period. Losing major pharmacy benefit management clients or suffering legislative margin compressions destroys capital efficiency across vertically integrated business units. Returns failing to exceed financing costs erode enterprise value and undermine the rationale for large-scale vertical healthcare consolidation.
